The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

George Tidmarsh left the agency amid accusations of misusing his authority and after clashing with another top official.

Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

George Tidmarsh, the FDA's top drug regulator, has been placed on leave after being accused of abusing his regulatory ...

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...

George Tidmarsh, a biopharma industry veteran who’s helmed CDER for a little more than three months, resigned yesterday after being placed on administrative leave two days earlier amid a Health and ...

The U.S. FDA once again has a leadership gap at the top of its drug center, which already has been ravaged this year by massive terminations, resignations and retirements of senior leaders. George ...

The FDA's Center for Drug Evaluation and Research, or CDER, has established a new center for communication between CDER staff and stakeholders involved in clinical trials, according to an April 15 ...

In January 2024, the Office of Compliance at the FDA’s Center for Drug Evaluation Research (CDER) released its Annual Report for FY2023. The Annual Report contains several useful pieces of information ...